Scientists develop the weekly injection of Parkinson to transform patient care

A new weekly injectable drug could transform the life of more than eight million people living with Parkinson’s disease, potentially replacing the need for daily pills.

Scientists from the University of South Australia (UNISA) have developed an injectable formulation with prolonged action which provides two key drugs from Parkinson for an entire week.

There is currently no remedy for Parkinson, which is the second largest common neurological disorder, affecting more than a million Americans, according to the Parkinson Foundation.

Stanford scientists were completely surprised “by the potential discovery of Parkinson’s treatment

To manage symptoms such as tremors, rigidity and slow movements, patients generally take daily oral drugs, such as levodopa and carbidopa, according to the university press release.

This method can be particularly difficult for people who find it difficult to swallow or who are otherwise unable to take the pills in a coherent manner, resulting in irregular drug levels, an increase in side effects and reduced efficiency.

Scientists from the University of South Australia have developed an injectable formulation with prolonged action which provides two key drugs from Parkinson for an entire week. (istock)

Levodopa is “gold therapy for Parkinson”, according to the principal researcher, Professor Sanjay Garg in the United Unisa, but his short lifespan means that she must be taken several times a day.

The researchers tested an injection gel implant which combines a biodegradable substance approved by the FDA with a substance sensitive to the pH to obtain a release of controlled and sustained drugs.

Parkinson patients who take “magic fungi” see key advantages, study results

The gel is injected by a single blow under the skin or in muscle tissue, which means that it is not necessary for a surgical implant and discomfort is minimal, they noted.

The team noted that the frost had gradually released Parkinson Keys (90% of the drug Levodopa and 81% of carbidopa) over a week.

The results were published in the journal Drug Delivery and Translational Research.

To manage symptoms such as tremors, rigidity and slow movement, patients usually take daily oral drugs. (istock)

“Reducing the frequency of dosage several times a day to a weekly injection is a major step in Parkinson therapy,” Garg said in the press release. “We are not only improving how the drug is issued; we improve the lives of patients.”

Vast laboratory tests have confirmed the efficiency and safety of the system.

“We are not only improving how the drug is issued; we improve the lives of patients.”

The implant degraded more than 80% in a week and has not shown no significant toxicity in cellular viability tests.

“The implications of this research are deep,” added Garg.

Click here to obtain the Fox News app

Deepa Nakmode, a doctoral student at the University of South Australia, noted that this method is designed to release levodopa and carbidopa regularly in a week, maintaining coherent plasma levels and reducing the risks associated with the fluctuation of drug concentrations.

“After years of targeted research, it is incredibly rewarding to see our innovation in prolonged action injectables for Parkinson’s disease at this stage,” he said in the press release.

The invention of the team has now been filed for an Australian patent, added Nakmode.

Vast laboratory tests have confirmed the effectiveness and safety of the new drug, the researchers noted. (istock)

Technology could also be adapted to other chronic conditions, such as cancer, diabetes, neurodegenerative disorders, chronic pain and infections that require long -term medication administration, according to Garg.

Click here to register for our Health Newsletter

The system can be set to release medication over a period from a few days to several weeks, depending on therapeutic needs.

For more health items, visit www.foxnews.com/health

Scientists hope to start clinical trials in the near future and explore opportunities to make freezing available in trade.